VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
NCT ID: NCT05156125
Last Updated: 2024-11-13
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
213 participants
INTERVENTIONAL
2021-11-30
2026-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study consists of a 28-day Screening Period (to see if a participant qualifies for the study), a 13-week double-blind period (a participant receives either active Dose A, Dose B or Placebo), a Long-Term Extension (LTE) Treatment Period of up to 39 weeks, an Open-Label Extension (OLE) Treatment Period of up to 143 weeks, and a 2-week Follow-Up Period. The maximal duration of treatment including the Induction Period, LTE and OLE will be 36 months.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis
NCT02958865
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)
NCT03558152
Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis
NCT03221036
A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis
NCT04613518
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
NCT01759056
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study consists of a 28-day Screening Period, a 13-week double-blind Induction Treatment Period (including 7 days of titration followed by 12 weeks of treatment at the assigned dose), a Long-Term Extension (LTE) Treatment Period of up to 39 weeks, an Open-Label Extension (OLE) Treatment Period of up to 143 weeks, and a 2-week Follow-Up Period. The maximal duration of treatment including the Induction Period, LTE and OLE will be 36 months.
Objectives Primary Objective
• Assess the efficacy of VTX002 when administered for 13 weeks on clinical remission
Secondary Objectives
* Assess the efficacy of VTX002 when administered for 13 weeks on endoscopic changes, symptomatic response and remission, histology, and mucosal healing
* Assess the safety and tolerability of VTX002
* Assess the pharmacokinetics (PK) of VTX002
Long-Term and Open-Label Extension Objectives
* Assess the efficacy of VTX002 through the LTE and OLE Treatment Periods on endoscopic changes, symptomatic response and remission, histology, and mucosal healing
* Assess the safety of VTX002 through the LTE and OLE Treatment Periods
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
VTX002 Dose A
VTX002 Dose A tablet administered orally once daily
VTX002
Dose A tablet administered orally once daily
VTX002 Dose B
VTX002 Dose B tablet administered orally once daily
VTX002
Dose B Tablet administered orally once daily
Placebo
Placebo tablet administered orally once daily
Placebo
Placebo Tablet for VTX002 administered orally once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VTX002
Dose A tablet administered orally once daily
VTX002
Dose B Tablet administered orally once daily
Placebo
Placebo Tablet for VTX002 administered orally once daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Active UC confirmed by endoscopy
Exclusion Criteria
* Diagnosis of Crohn's disease (CD) or indeterminate colitis or the presence or history of a fistula consistent with CD
* Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Oppilan Pharma Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Snehal Naik, PhD
Role: STUDY_DIRECTOR
Ventyx Biosciences, Inc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Site # 840030
Garden Grove, California, United States
Local Site # 840026
Lancaster, California, United States
Local Site # 840040
San Diego, California, United States
Local Site # 840001
Ventura, California, United States
Local Site # 840049
Kissimmee, Florida, United States
Local Site # 840006
Miami, Florida, United States
Local Site # 840018
Atlanta, Georgia, United States
Local Site # 840046
New Albany, Indiana, United States
Local Site # 840042
Shreveport, Louisiana, United States
Local Site # 840044
Ypsilanti, Michigan, United States
Local Site # 840043
Dayton, Ohio, United States
Local Site # 840010
Oklahoma City, Oklahoma, United States
Local Site # 840045
Myrtle Beach, South Carolina, United States
Local Site # 840013
Garland, Texas, United States
Local Site # 8400039
Lubbock, Texas, United States
Local Site # 840033
McAllen, Texas, United States
Local Site # 840007
San Marcos, Texas, United States
Local Site # 840016
Southlake, Texas, United States
Local Site # 840028
Tyler, Texas, United States
Local Site # 100002
Rousse, , Bulgaria
Local Site # 100005
Rousse, , Bulgaria
Local Site # 203002
Hradec Králové, , Czechia
Local Site # 203001
Slaný, , Czechia
Local Site # 203004
Ústí nad Labem, , Czechia
Local Site # 250004
Caen, , France
Local Site # 250001
Nantes, , France
Local Site # 250003
Vandœuvre-lès-Nancy, , France
Local Site # 268001
Tbilisi, , Georgia
Local Site # 268002
Tbilisi, , Georgia
Local Site # 268003
Tbilisi, , Georgia
Local Site # 268004
Tbilisi, , Georgia
Local Site # 268005
Tbilisi, , Georgia
Local Site # 268006
Tbilisi, , Georgia
Local Site # 276005
Berlin, , Germany
Local Site # 276008
Brandenburg, , Germany
Local Site # 276007
Duisburg, , Germany
Local Site # 276009
Halle, , Germany
Local Site # 276003
Nordhausen, , Germany
Local Site # 348004
Békéscsaba, , Hungary
Local Site # 348001
Budapest, , Hungary
Local Site # 348003
Budapest, , Hungary
Local Site # 348002
Székesfehérvár, , Hungary
Local Site # 356001
Ahmedabad, , India
Local Site # 356003
Jaipur, , India
Local Site # 356005
Sūrat, , India
Local Site # 380009
Milan, , Italy
Local Site # 380001
Negrar, , Italy
Local Site # 380004
Pavia, , Italy
Local Site # 380008
Rome, , Italy
Local Site # 380002
San Giovanni Rotondo, , Italy
Local Site # 440002
Panevezys, , Lithuania
Local Site # 440001
Vilnius, , Lithuania
Local Site # 616010
Bydgoszcz, , Poland
Local Site # 616012
Jelenia Góra, , Poland
Local Site # 616001
Lodz, , Poland
Local Site # 616017
Lodz, , Poland
Local Site # 616015
Lublin, , Poland
Local Site # 616004
Oświęcim, , Poland
Local Site # 616011
Piotrkow Trybunalski, , Poland
Local Site # 616008
Poznan, , Poland
Local Site # 616014
Rzeszów, , Poland
Local Site # 616007
Sosnowiec, , Poland
Local Site # 616003
Warsaw, , Poland
Local Site # 616006
Warsaw, , Poland
Local Site # 616002
Wroclaw, , Poland
Local Site # 616009
Wroclaw, , Poland
Local Site # 616013
Wroclaw, , Poland
Local Site # 688002
Belgrade, , Serbia
Local Site # 688003
Belgrade, , Serbia
Local Site # 688004
Belgrade, , Serbia
Local Site # 688001
Zrenjanin, , Serbia
Local Site # 703001
Košice, , Slovakia
Local Site # 703003
Prešov, , Slovakia
Local Site # 703002
Šahy, , Slovakia
Local Site # 410003
Daegu, , South Korea
Local Site # 410002
Seoul, , South Korea
Local Site # 410004
Wŏnju, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sands BE, Panaccione R, D'Haens G, Schreiber S, Jairath V, DuVall A, Kierkus J, Walczak M, Naik S, Gilder K, Lindstrom B, Ogilvie K, Sandborn WJ, Vermeire S, Rubin DT, Peyrin-Biroulet L, Danese S. Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial. Lancet Gastroenterol Hepatol. 2025 Mar;10(3):210-221. doi: 10.1016/S2468-1253(24)00386-8. Epub 2025 Jan 7.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VTX002-201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.